Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (9): 812-817.DOI: 10.3969/j.issn.1673-8640.2023.09.002
Previous Articles Next Articles
WANG Rong1, XING Lianxiang1, HUANG Keliang1, LI Xin2()
Received:
2022-07-07
Revised:
2023-03-23
Online:
2023-09-30
Published:
2023-11-29
CLC Number:
WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35[J]. Laboratory Medicine, 2023, 38(9): 812-817.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.09.002
基因 名称 | 引物序列(5'~3') | 产物长度/bp |
---|---|---|
TRIM35 | F:GAGGTGCTGGCACATGAGAT | 112 |
R:GCTCCATGGTGCAGAAGAGT | ||
GAPDH | F:CACCCACTCCTCCACCTTTG | 110 |
R:CCACCACCCTGTTGCTGTAG | ||
miR-374 | F:ATATAATACAACCTGCTAAGTG | 134 |
R:GCAGGGTCCGAGGTATTC | ||
U6 | F:CTCGCTTCGGCAGCACA | 94 |
R:AACGCTTCACGAATTTGCGT |
基因 名称 | 引物序列(5'~3') | 产物长度/bp |
---|---|---|
TRIM35 | F:GAGGTGCTGGCACATGAGAT | 112 |
R:GCTCCATGGTGCAGAAGAGT | ||
GAPDH | F:CACCCACTCCTCCACCTTTG | 110 |
R:CCACCACCCTGTTGCTGTAG | ||
miR-374 | F:ATATAATACAACCTGCTAAGTG | 134 |
R:GCAGGGTCCGAGGTATTC | ||
U6 | F:CTCGCTTCGGCAGCACA | 94 |
R:AACGCTTCACGAATTTGCGT |
临床病理特征 | 例数 | miR-374 |
---|---|---|
年龄 | ||
<60岁 | 16 | 3.52±1.68 |
≥60岁 | 26 | 3.30±1.64 |
t值 | 0.389 1 | |
P值 | 0.678 4 | |
肿瘤大小 | ||
<3 cm | 18 | 2.64±1.20 |
≥3 cm | 24 | 3.81±1.67 |
t值 | 2.148 3 | |
P值 | 0.023 2 | |
TNM分期 | ||
T1~T2 | 26 | 3.40±1.51 |
T3~T4 | 16 | 3.29±1.63 |
t值 | 0.532 6 | |
P值 | 0.551 4 | |
淋巴转移 | ||
无 | 14 | 3.80±1.55 |
有 | 28 | 2.32±1.07 |
t值 | 7.724 2 | |
P值 | 0.002 1 | |
远隔转移 | ||
无 | 31 | 2.49±1.54 |
有 | 11 | 3.59±1.49 |
t值 | 1.934 5 | |
P值 | 0.034 9 |
临床病理特征 | 例数 | miR-374 |
---|---|---|
年龄 | ||
<60岁 | 16 | 3.52±1.68 |
≥60岁 | 26 | 3.30±1.64 |
t值 | 0.389 1 | |
P值 | 0.678 4 | |
肿瘤大小 | ||
<3 cm | 18 | 2.64±1.20 |
≥3 cm | 24 | 3.81±1.67 |
t值 | 2.148 3 | |
P值 | 0.023 2 | |
TNM分期 | ||
T1~T2 | 26 | 3.40±1.51 |
T3~T4 | 16 | 3.29±1.63 |
t值 | 0.532 6 | |
P值 | 0.551 4 | |
淋巴转移 | ||
无 | 14 | 3.80±1.55 |
有 | 28 | 2.32±1.07 |
t值 | 7.724 2 | |
P值 | 0.002 1 | |
远隔转移 | ||
无 | 31 | 2.49±1.54 |
有 | 11 | 3.59±1.49 |
t值 | 1.934 5 | |
P值 | 0.034 9 |
[1] |
JOKAR N, VELIKYAN I, AHMADZADEHFAR H, et al. Theranostic approach in breast cancer:a treasured tailor for future oncology[J]. Clin Nucl Med, 2021, 46(8):e410-e420.
DOI URL |
[2] |
LI C L, YANG D, CAO X, et al. Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain[J]. Oncol Lett, 2017, 13(5):3889-3895.
DOI URL |
[3] | LAGES E, IPAS H, GUTTIN A, et al. MicroRNAs:molecular features and role in cancer[J]. Front Biosci(Landmark Ed), 2012, 17(7):2508-2540. |
[4] |
LUO J, ZHAO Q, ZHANG W, et al. A novel panel of microRNAs provides a sensitive and specific tool for the diagnosis of breast cancer[J]. Mol Med Rep, 2014, 10(2):785-791.
DOI PMID |
[5] |
KIMURA F, SUZU S, NAKAMURA Y, et al. Cloning and characterization of a novel RING-B-box-coiled-coil protein with apoptotic function[J]. J Biol Chem, 2003, 278(27):25046-25054.
DOI PMID |
[6] |
WANG Y, YAN S, YANG B, et al. TRIM35 negatively regulates TLR7- and TLR9-mediated type Ⅰ interferon production by targeting IRF7[J]. FEBS Lett, 2015, 589(12):1322-1330.
DOI URL |
[7] | 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10):954-1040. |
[8] |
GIAQUINTO A N, SUNG H, MILLER K D, et al. Breast cancer statistics,2022[J]. CA Cancer J Clin, 2022, 72(6):524-541.
DOI URL |
[9] |
JIANG Y, JIANG Z, WANG M, et al. Current understandings and clinical translation of nanomedicines for breast cancer therapy[J]. Adv Drug Deliv Rev, 2022, 180:114034.
DOI URL |
[10] |
NATHANSON S D, DETMAR M, PADERA T P, et al. Mechanisms of breast cancer metastasis[J]. Clin Exp Metastasis, 2022, 39(1):117-137.
DOI |
[11] |
IACONA J R, LUTZ C S. MiR-146a-5p:expression,regulation,and functions in cancer[J]. Wiley Interdiscip Rev RNA, 2019, 10(4):e1533.
DOI URL |
[12] |
WU J, WANG Y, SHANG L, et al. Five common functional polymorphisms in microRNAs and susceptibility to breast cancer:an updated meta-analysis[J]. Genet Test Mol Biomarkers, 2018, 22(6):350-358.
DOI URL |
[13] | SANDIFORD O A, MOORE C A, DU J, et al. Human aging and cancer:role of miRNA in tumor microenvironment[J]. Adv Exp Med Biol, 2018, 1056:137-152. |
[14] |
ZHANG K, WANG Y Y, XU Y, et al. A two-miRNA signature of upregulated miR-185-5p and miR-362-5p as a blood biomarker for breast cancer[J]. Pathol Res Pract, 2021, 222:153458.
DOI URL |
[15] |
BIAN H, ZHOU Y, ZHOU D, et al. The latest progress on miR-374 and its functional implications in physiological and pathological processes[J]. J Cell Mol Med, 2019, 23(5):3063-3076.
DOI PMID |
[16] |
HE H C, HAN Z D, DAI Q S, et al. Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients[J]. BMC Genomics, 2013, 14:757.
DOI |
[17] |
RAHIMI Z, GHORBANI Z, MOTAMED H, et al. Aberrant expression profile of miR-32,miR-98 and miR-374 in chronic lymphocytic leukemia[J]. Leuk Res, 2021, 111:106691.
DOI URL |
[18] |
GAO J, BAI S, WANG Y, et al. MiR-374b targets GATA3 to promote progression and development of glioblastoma via regulating SEMA3B[J]. Neoplasma, 2019, 66(4):543-554.
DOI PMID |
[19] |
HATAKEYAMA S. TRIM family proteins:roles in autophagy,immunity,and carcinogenesis[J]. Trends Biochem Sci, 2017, 42(4):297-311.
DOI URL |
[20] |
EBERHARDT W, HAEUSSLER K, NASRULLAH U, et al. Multifaceted roles of TRIM proteins in colorectal carcinoma[J]. Int J Mol Sci, 2020, 21(20):7532.
DOI URL |
[21] |
CHEN Z, WANG Z, GUO W, et al. TRIM35 interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma[J]. Oncogene, 2015, 34(30):3946-3956.
DOI PMID |
[22] |
WANG R, HUANG K L, XING L X. TRIM35 functions as a novel tumor suppressor in breast cancer by inducing cell apoptosis through ubiquitination of PDK1[J]. Neoplasma, 2022, 69(2):370-382.
DOI URL |
[23] |
LIANG A L, ZHANG T T, ZHOU N, et al. MiRNA-10b sponge:an anti-breast cancer study in vitro[J]. Oncol Rep, 2016, 35(4):1950-1958.
DOI URL |
[24] |
WU H, GUO X, JIAO Y, et al. TRIM35 ubiquitination regulates the expression of PKM2 tetramer and dimer and affects the malignant behaviour of breast cancer by regulating the Warburg effect[J]. Int J Oncol, 2022, 61(6):144.
DOI URL |
[1] | CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578. |
[2] | ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429. |
[3] | LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239. |
[4] | LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147. |
[5] | GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206,miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068. |
[6] | SHANG Zhenjun, WEI Wei, LIU Ruihan. Effect of inhibiting PTBP1 on the proliferation and invasiveness of choroidal melanoma cells [J]. Laboratory Medicine, 2023, 38(1): 51-55. |
[7] | WANG Xiaoye, DONG Guoyou, LIU Zhiying. Relations of ZEB2 and E-Cad expressions in breast cancer tissues with prognosis [J]. Laboratory Medicine, 2022, 37(9): 815-820. |
[8] | YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517. |
[9] | YE Jingwen, SHEN Yunyue, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of MAPK/ERK signaling pathway in reversing endocrine resistance of breast cancer [J]. Laboratory Medicine, 2022, 37(4): 342-348. |
[10] | LI Mingwu, WANG Qinzhi, SUN Farui. Influence of MUC16 on the cell proliferation and invasion of osteosarcoma cells [J]. Laboratory Medicine, 2022, 37(10): 979-983. |
[11] | ZHANG Xinyue, CHEN Liang, ZHENG Yu. Correlation between serum C peptide and insulin-like growth factor binding protein 3 and the risk of breast cancer patient death [J]. Laboratory Medicine, 2022, 37(1): 36-40. |
[12] | LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718. |
[13] | YUAN Muge, WU Wenjian, HU Zhaohui, CHEN Jiachang, YU Shihui, OU Xiaohua, MAO Linlin, WU Haiyan. Germline mutation detection in early-stage breast cancer by next-generation sequencing [J]. Laboratory Medicine, 2021, 36(3): 325-329. |
[14] | LIU Xiufen, AO Hongfeng, AO Jinping. Expression of programmed cell death 5 in breast cancer and its clinical value [J]. Laboratory Medicine, 2021, 36(11): 1151-1158. |
[15] | JIN Shu, ZHU Qi, ZHU Yuan, YUAN Ya, CAI Xiaoyao, ZHANG Ji, YAN Peiyi. Methylation level and mRNA expression of CpG island of HER2 gene in breast cancer and its adjacent tissues [J]. Laboratory Medicine, 2020, 35(5): 481-486. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||